Open AccessP1047: REAL‐WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST‐POLYCYTHEMIA VERA MYELOFIBROSIS OR POST‐ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
Author(s) -
Xu Z.,
Duan M.,
Jiang Q.,
Leng Q.,
Xu N.,
Zhang Y.,
Zhao C.,
Wu W.,
Zhang Q.,
Fu J.,
Zhang J.,
Fu R.,
Yan Z.,
Zhang J.,
Lin C.,
Ouyang G.,
Wang Z.,
Ma L.,
Hao H.,
Li X.,
Ran S.,
Chen Y.,
Li T.,
Xiao Z.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847056.62279.a3
Subject(s) - ruxolitinib , myelofibrosis , medicine , polycythemia vera , essential thrombocythemia , discontinuation , population , adverse effect , surgery , pediatrics , bone marrow , environmental health